Home / Tag Archives: TRI

Tag Archives: TRI

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

— No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study OSAKA, Japan, Aug. 29, 2014 /PRNewswire/ — Takeda Pharmaceutical Company Limited ("Takeda") today announced…

Read More »

Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study

— Company To Pursue Next Stage of Development REDWOOD CITY, California, Aug. 15, 2014  /PRNewswire/ — Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in…

Read More »

Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma

DARMSTADT, Germany, July 29, 2014 /PRNewswire/ — First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel cell carcinoma (mMCC)  mMCC is a…

Read More »

TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform

TEANECK, N.J., July 24, 2014 /PRNewswire/ — Cognizant (NASDAQ: CTSH) today announced that it has been selected by TransCelerate BioPharma Inc., a non-profit organization with membership representation from 19 major pharmaceutical companies, to develop a first-of-its-kind,…

Read More »

International team sheds new light on biology underlying schizophrenia

CAMBRIDGE, Mass., July 22, 2014 /PRNewswire/ — As part of a multinational, collaborative effort, researchers from the Broad Institute, Massachusetts General Hospital (MGH), and scores of other institutions from all over the world have helped identify…

Read More »

Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)

REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ — Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept (Enbrel®), in chronic plaque psoriasis (the RaPsOdy trial). This…

Read More »